Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) saw an uptick in trading volume on Thursday . 5,841 shares changed hands during mid-day trading, an increase of 68% from the previous session’s volume of 3,482 shares.The stock last traded at $9.45 and had previously closed at $9.45.

Bavarian Nordic Trading Up 1.6%

The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of 12.40 and a beta of 1.19. The stock’s 50 day moving average price is $9.95 and its two-hundred day moving average price is $9.93.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.37%. The business had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.